We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

BEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01453595
Recruitment Status : Terminated (Given the number of toxicities seen and the difficulty with patient retention in the dose escalation portion, the sponsor decided to close the trial.)
First Posted : October 18, 2011
Results First Posted : February 29, 2016
Last Update Posted : February 29, 2016
Sponsor:
Collaborator:
Information provided by (Responsible Party):

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Condition: Renal Cancer
Intervention: Drug: BEZ235

  Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Cohort 1: BEZ235 400mg Cohort 1: BEZ235 400mg by mouth twice daily
Cohort -1: BEZ235 200mg Cohort -1: BEZ235 200mg by mouth twice daily
Cohort -1a: BEZ235 300mg Cohort -1a: BEZ235 300mg by mouth twice daily

Participant Flow:   Overall Study
    Cohort 1: BEZ235 400mg   Cohort -1: BEZ235 200mg   Cohort -1a: BEZ235 300mg
STARTED   2   6   2 
COMPLETED   0   5   0 
NOT COMPLETED   2   1   2 
Dose Limiting Toxicity (DLT)                2                1                2 



  Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Cohort 1: BEZ235 400mg Cohort 1: BEZ235 400mg by mouth twice daily
Cohort -1: BEZ235 200mg Cohort -1: BEZ235 200mg by mouth twice daily
Cohort -1a: BEZ235 300mg Cohort -1a: BEZ235 300mg by mouth twice daily
Total Total of all reporting groups

Baseline Measures
   Cohort 1: BEZ235 400mg   Cohort -1: BEZ235 200mg   Cohort -1a: BEZ235 300mg   Total 
Overall Participants Analyzed 
[Units: Participants]
 2   6   2   10 
Age 
[Units: Participants]
       
<=18 years   0   0   0   0 
Between 18 and 65 years   0   5   1   6 
>=65 years   2   1   1   4 
Gender 
[Units: Participants]
       
Female   0   2   1   3 
Male   2   4   1   7 
Region of Enrollment 
[Units: Participants]
       
United States   2   6   2   10 


  Outcome Measures

1.  Primary:   Objective Response Rate (ORR)   [ Time Frame: 1 year ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
Given the number of toxicities seen and the difficulty with patient retention in the dose escalation portion, the sponsor decided to close the trial.


  More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: Dr. Martin Voss
Organization: Memorial Sloan Kettering Cancer Center
phone: 646-422-4631
e-mail: vossm@mskcc.org


Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier: NCT01453595     History of Changes
Other Study ID Numbers: 11-080
First Submitted: October 13, 2011
First Posted: October 18, 2011
Results First Submitted: December 14, 2015
Results First Posted: February 29, 2016
Last Update Posted: February 29, 2016